Filtered By:
Source: Nanomedicine: Nanotechnology, Biology and Medicine
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 65 results found since Jan 2013.
A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin
Publication date: Available online 19 October 2016 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Phei Er Saw, Jinho Park, Sangyong Jon, Omid C. Farokhzad A major problem with cancer chemotherapy begins when cells acquire resistance. Drug-resistant cancer cells typically upregulate multi-drug resistance proteins such as P-glycoprotein (P-gp). However, the lack of overexpressed surface biomarkers has limited the targeted therapy of drug-resistant cancers. Here we report a drug-delivery carrier decorated with a targeting ligand for a surface marker protein Extra-domain B(EDB) specific to drug-resistant...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - October 28, 2016 Category: Nanotechnology Source Type: research
Single-Step Microfluidic Synthesis of Transferrin-Conjugated Lipid Nanoparticles for siRNA Delivery
In this study, a single-step process based on microfluidic focusing (MF) was employed to synthesize transferrin-conjugated lipid nanoparticles (Tf-LNPs) and the method was compared with a multi-steps bulk mixing (BM) method. The results indicate that this single-step MF process enables rapid and efficient synthesis of Tf-LNPs, which were named Tf-LNPs-MF. Tf-LNPs-MF was shown to have a smaller size and more uniform structures compared to LNPs produced by multi-steps BM method (Tf-LNPs-BM). Furthermore, efficient cellular uptake of Tf-LNPs-MF in vitro as well as greater tumor inhibition in vivo proved that Tf-LNPs-MF had hi...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - October 9, 2016 Category: Nanotechnology Source Type: research
Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo
This study highlights the ability of incorporating a folate ligand into CD.siRNA nanoparticles to allow for targeted delivery of siRNA to prostate cancer cells via the PSMA. Graphical abstract
Source: Nanomedicine: Nanotechnology, Biology and Medicine - August 27, 2016 Category: Nanotechnology Source Type: research
Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo
Publication date: Available online 20 August 2016 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Alexander Ewe, Omkar Panchal, Shashank Reddy Pinnapireddy, Udo Bakowsky, Susanne Przybylski, Achim Temme, Achim Aigner Therapeutic applications of RNA interference (RNAi) require efficient siRNA delivery strategies in vivo. Combining lipid-based carriers with polymeric nanoparticles offers the favourable properties of both systems. This is the first study to explore polyethylenimine-based lipopolyplexes comprising a low-molecular weight PEI and the phospholipid DPPC for therapeutic siRNA use. Lipopolyplex...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - August 20, 2016 Category: Nanotechnology Source Type: research
Quantum dots-hemin: Preparation and application in the absorption of heme iron
Publication date: October 2016 Source:Nanomedicine: Nanotechnology, Biology and Medicine, Volume 12, Issue 7 Author(s): Lina Geng, Xianglin Duan, Yan Wang, Yashuo Zhao, Guofen Gao, Delong Liu, Yan-Zhong Chang, Peng Yu The absorption mechanism of heme iron remains unclear due to the limit of labeling techniques. Quantum dots (QDs) are powerful fluorescent probes resistant to photobleaching, however, there is no data about the application of QDs in heme iron absorption. Herein, we prepared hemin-coated CdSe/ZnS (QDs-hemin), and studied their absorption in vitro and in vivo. Results showed that QDs-hemin had uniform...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - June 9, 2016 Category: Nanotechnology Source Type: research
Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2
Publication date: Available online 22 March 2016 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Jae-Su Moon, Seung-Hoon Lee, Song-Hee Han, Eun-Jung Kim, Hee Cho, Wooseong Lee, Mi-Kyung Kim, Tae-Eun Kim, Hyun-Ji Park, Jin-Kyu Rhee, Seong-Jun Kim, Seung-Woo Cho, Seung Hyun Han, Jong-Won Oh Host-targeting antivirals have an advantage over direct-acting antivirals in that they have a high genetic barrier to resistance. Here, we describe in vivo anti-hepatitis C virus (HCV) efficacy of a potent siRNA targeting the protein kinase C-related kinase 2 (PRK2), which phosphorylates HCV NS5B RNA-d...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - March 21, 2016 Category: Nanotechnology Source Type: research
Intracellular Trafficking and Exocytosis of a Multi-Component siRNA Nanocomplex
The objective of this study is to study post internalization trafficking of this siRNA nanocomplex and its multiple components like siRNA, protamine, and streptavidin, in HSCs. After internalization, the nanocomplex entrapped in early endosomes undergoes three possible routes including endosomal escape, exocytosis, and entrapment in lysosomes. Significant amount of siRNA dissociates form the nanocomplex to exert silencing activity. After escaping from endosomes, protamine dissociates from the nanocomplex and stays inside the cytoplasm. Golgi complex plays an important role in exocytosis of the nanocomplex. We also demonstr...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - March 11, 2016 Category: Nanotechnology Source Type: research
Robust neuroprotective effects of intranasally delivered iNOS siRNA encapsulated in gelatin nanoparticles in the postischemic brain
Publication date: Available online 3 March 2016 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Il-Doo Kim, Elizabeth Sawicki, Hye-Kyung Lee, Eun-Hwa Lee, Heon Joo Park, Pyung-Lim Han, Kyekyoon (Kevin) Kim, Hyungsoo Choi, Ja-Kyeong Lee The therapeutic efficacy of intranasal iNOS siRNA delivery was investigated in the postischemic rat brain after encapsulating on in gelatin nanoparticles (GNPs; diameter 188.0±60.9 nm) cross-linked with 0.0667% glutaraldehyde (GA). Intranasally delivered GNPs were found in extracellular and intracellular compartments of many brain regions, including the olfac...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - March 4, 2016 Category: Nanotechnology Source Type: research
Intranasal Brain Delivery of Cationic Nanoemulsion-Encapsulated TNFα siRNA in Prevention of Experimental Neuroinflammation
Publication date: Available online 6 January 2016 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Sunita Yadav, Srujan K. Gandham, Riccardo Panicucci, Mansoor M. Amiji Neuroinflammation is a hallmark of acute and chronic neurodegenerative disorders. Activated microglia and secreted factors such as tumor necrosis factor-alpha (TNFα) are key mediators of neuroinflammation and may contribute to neuronal dysfunction. The main aim of this study was to evaluate the therapeutic efficacy of intranasal cationic nanoemulsions encapsulating an anti-TNFα siRNA, for potential anti-inflammatory therapy, test...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - January 12, 2016 Category: Nanotechnology Source Type: research
Ultrasound-Responsive Microbubbles for Sonography-guided siRNA Delivery
Publication date: Available online 28 December 2015 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Ping Wang, Tinghui Yin, Jingguo Li, Bowen Zheng, Xiaoli Wang, Yiru Wang, Jian Zheng, Rongqin Zheng, Xintao Shuai RNA interfering is a gene therapeutic approach of great potential for cancer. However, tumor-targeted delivery of small interfering RNA (siRNA) solely based on the enhanced permeability and retention effect of nanocarriers is often insufficient. To address this challenge, siRNA encapsulated ultrasound-responsive microbubble (MB) was developed from polymeric siRNA micelles and liposo...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - December 29, 2015 Category: Nanotechnology Source Type: research
Designing idiosyncratic hmPCL-siRNA Nanoformulated Capsules for Silencing and Cancer Therapy
Publication date: Available online 10 November 2015 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Vijay Bhooshon Kumar, Himadri Medhi, Zhang Yong, Pradip Paik In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone (hmPCL) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~180 nm with shell thickness of 10-20 nm and mesopore size of ~5-10 nm in diameter. Idiosyncratic capsules are biocompatible which has been confirmed with normal lymphocyte, K562 leukaemia cancer cells and on HepG2/EGFP cancer cells. In ...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 10, 2015 Category: Nanotechnology Source Type: research
Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden
Publication date: October 2015 Source:Nanomedicine: Nanotechnology, Biology and Medicine, Volume 11, Issue 7 Author(s): James Finlay, Cai M. Roberts, Juyao Dong, Jeffrey I. Zink, Fuyuhiko Tamanoi, Carlotta A. Glackin Growth and progression of solid tumors depend on the integration of multiple pro-growth and survival signals, including the induction of angiogenesis. TWIST1 is a transcription factor whose reactivation in tumors leads to epithelial to mesenchymal transition (EMT), including increased cancer cell stemness, survival, and invasiveness. Additionally, TWIST1 drives angiogenesis via activation of IL-8 and C...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - August 17, 2015 Category: Nanotechnology Source Type: research
ROS-Induced Nanotherapeutic Approach for Ovarian Cancer Treatment Based on the Combinatorial Effect of Photodynamic Therapy and DJ-1 Gene Suppression
This study represents a novel approach for intraoperative ovarian cancer treatment based on the combinatorial effect of a targeted photodynamic therapy (PDT) associated with suppression of the DJ-1 protein, one of the key players in the ROS defense of cancer cells. To assess the potential of the developed therapy, dendrimer-based nanoplatforms for cancer-targeted delivery of near-infrared photosensitizer, phthalocyanine, and DJ-1 siRNA have been constructed. In vitro studies revealed that therapeutic efficacy of the combinatorial approach was enhanced when compared to PDT alone and this enhancement was more pronounced in o...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - August 2, 2015 Category: Nanotechnology Source Type: research
Multifunctional Selenium Nanoparticles: Chiral Selectivity of Delivering MDR-siRNA for Reversal of Multidrug Resistance and Real-time Biofluorescence Imaging
Publication date: Available online 8 May 2015 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Qingchang Chen , Qianqian Yu , Yanan Liu , Dhairya Bhavsar , Licong Yang , Xiaofan Ren , Dongdong Sun , Wenjing Zheng , Jie Liu , Lan-mei Chen In this paper, chiral selenium nanoparticles (L-SeNPs/D-SeNPs) modified with a dinuclear Ruthenium (II) complex were used to effectively deliver siRNA targeting the MDR1 gene. In this co-delivery system, the luminescent dinuclear Ruthenium (II) complex was developed to act as a gene carrier and anti-tumor drug, while offering luminescent imaging to follow the intracel...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - May 9, 2015 Category: Nanotechnology Source Type: research
Conformation-dependent binding and tumor-targeted delivery of siRNA by a designed TRBP2: Affibody fusion protein
Publication date: Available online 23 February 2015 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Ghulam Hassan Dar , Vijaya Gopal , Madhusudhana Rao Efficiency of systemically delivered siRNA in gene silencing is compromised due to lack of target-specific delivery and rapid clearance of siRNA by in vivo elimination pathways. We designed a fusion protein consisting of a dsRNA binding domain of Transactivation Response RNA Binding Protein (TRBP2) fused to ErbB2 binding affibody (AF) for target specific delivery of siRNA. Designated as TRAF, the fusion protein is stable and binds efficiently and spec...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - February 24, 2015 Category: Nanotechnology Source Type: research
